Alembic Pharmaceuticals gained 0.13% to Rs 599 after consolidated net profit jumped 37.89% to Rs 234.19 crore on 18.75% rise in net sales to Rs 1,209.13 crore in Q3 December 2019 over Q3 December 2018.
Consolidated profit before tax (PBT) rose 31.09% to Rs 276.28 crore in Q3 December 2019 as compared to Rs 210.75 crore in Q3 December 2018. The Q3 result was declared during trading hours today, 22 January 2020.
Commenting on the Q3 performance, Pranav Amin, the managing director of Alembic Pharmaceuticals, has stated that, It was a good quarter for the company led by strong growth in the International Markets. We launched 7 products in the US market during the quarter.
Alembic Pharmaceuticals is engaged developing formulations and active pharmaceutical ingredients (API).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app